Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Purchase Date: December 3, 2008.
- Purchase Price: 1,134.13 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,196,000,298 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 550,000 repurchased shares. Consequently, the Company's Treasury shareholding now represents 9.13% of total voting rights. The total number of shares in issue remains 5,196,000,298.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Investor Verification Checklist
- Verify the total cost of the repurchase (550,000 shares at 1,134.13 pence).
- Confirm the updated Treasury share percentage (9.13%) against total voting rights.
- Check the denominator for disclosure thresholds (5,196,000,298 shares in issue).
- Note that this filing does not contain operational or financial performance data for the period.